Trial Profile
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Gusacitinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Diffuse lymphoma; Follicular lymphoma; Large cell carcinoma; Lymphoma; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Asana BioSciences; Kirilys Therapeutics
- 13 Aug 2018 Status changed from recruiting to discontinued as per business decision.
- 05 Jun 2018 Results (n=46) assessing safety, tolerability, pharmacokinetics, serum markers of inflammation, and response presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 23 Jan 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.